MEDICO

Medico Remedies financials

Market cap
₹294 Cr
Sector
Healthcare

What Medico Remedies Limited does

Medico Remedies Limited is a pharmaceutical company that manufactures at its own plant in Palghar district, Maharashtra, overseen by a dedicated General Manager - Plant. The company maintains separate in-house Production (Technical) and Quality Control departments as well as a Marketing and Export department that handles overseas markets. As of FY25 it operates as a standalone entity with no subsidiaries, joint ventures or associate companies.

Manufacturing plants
1 (Palghar, Maharashtra)
Subsidiaries/JVs/Associates
None (standalone, FY25)
Headquarters Mumbai, Maharashtra Company website

Quarterly results

Q1 FY27: revenue up 81.4%, net profit up 38.5% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue39 39 41 38 53 +34%59 +49%57 +38%69 +81%
EBITDA2 3 7 3 3 +13%4 +39%7 +7%3 +17%
Net profit2 3 4 2 3 +66%3 +10%6 +35%3 +38%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −5.6% 1Y

₹35.0₹40.0₹45.0₹50.0₹55.0Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹39.24 on 10 Sept 2025 → ₹37.05. High ₹54.24 (24 Dec 2025), low ₹32.76 (30 Mar 2026).

Financials, as filed

Revenue grew 13.7% a year over 3 years, FY23 to FY26. Operating margin widened to 8.3%.

Year endingFY23FY24FY25FY26
Revenue₹140 Cr₹145 Cr₹151 Cr₹206 Cr
Operating profit₹10 Cr₹13 Cr₹15 Cr₹17 Cr
Operating margin6.8%8.9%9.9%8.3%
Interest₹1 Cr₹1 Cr₹1 Cr₹2 Cr
Depreciation₹3 Cr₹3 Cr₹3 Cr₹3 Cr
Net profit₹7 Cr₹8 Cr₹10 Cr₹13 Cr
Net margin5.2%5.7%6.7%6.4%
Cash from operations₹8 Cr₹2 Cr₹5 Cr₹6 Cr
Free cash flow₹2 Cr₹0 Cr₹2 Cr₹1 Cr
ROCE21.0%21.0%21.0%23.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹4 Cr₹17 Cr₹17 Cr₹17 Cr₹17 Cr₹17 Cr
Reserves₹28 Cr₹20 Cr₹27 Cr₹36 Cr₹50 Cr₹59 Cr
Borrowings₹15 Cr₹13 Cr₹10 Cr₹8 Cr₹13 Cr₹19 Cr
Other liabilities₹28 Cr₹28 Cr₹34 Cr₹36 Cr₹58 Cr₹59 Cr
Total liabilities₹76 Cr₹77 Cr₹87 Cr₹96 Cr₹137 Cr₹153 Cr
Fixed assets₹15 Cr₹18 Cr₹22 Cr₹21 Cr₹21 Cr₹20 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹3 Cr
Investments₹1 Cr₹0 Cr₹1 Cr₹2 Cr₹2 Cr₹2 Cr
Other assets₹59 Cr₹59 Cr₹64 Cr₹73 Cr₹114 Cr₹129 Cr
Total assets₹76 Cr₹77 Cr₹87 Cr₹96 Cr₹137 Cr₹153 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, the public added +1.22 pp while promoters trimmed −1.21 pp. The shareholder count shrank 4% to 15,863.

Promoters
61.4%
FIIs
0.1%
Public
38.5%

Since Jun 2025

  • Public +1.22 pp
  • Promoters −1.21 pp
  • FIIs +0.01 pp

How it drifted, 12 quarters

Over this window the public went from 25.6% to 38.5% — +13.0 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 73.3%, FIIs 1.1%, Public 25.6%.Dec '23: Promoters 73.3%, FIIs 1.3%, Public 25.4%.Mar '24: Promoters 73.3%, FIIs 0.3%, DIIs 0.7%, Public 25.6%.Jun '24: Promoters 73.3%, FIIs 0.2%, DIIs 1.0%, Public 25.5%.Sep '24: Promoters 73.3%, FIIs 0.2%, DIIs 1.0%, Public 25.5%.Dec '24: Promoters 66.8%, FIIs 0.4%, DIIs 0.8%, Public 32.0%.Mar '25: Promoters 63.8%, FIIs 0.1%, DIIs 0.0%, Public 36.1%.Jun '25: Promoters 62.6%, FIIs 0.1%, DIIs 0.0%, Public 37.3%.Sep '25: Promoters 61.4%, FIIs 0.3%, DIIs 0.0%, Public 38.3%.Dec '25: Promoters 61.4%, FIIs 0.5%, Public 38.1%.Mar '26: Promoters 61.4%, FIIs 0.0%, Public 38.6%.Jun '26: Promoters 61.4%, FIIs 0.1%, Public 38.5%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Medico Remedies Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Haresh Kapurlal Mehta 20.22%unchanged
Mehta Rishit Hareshbhai 12.65%unchanged
Harshit Haresh Mehta 10.39%unchanged
Rita H Mehta 8.05%unchanged
Ravi Goyal 6.83%unchanged
Shweta Harshit Mehta 5.88%unchanged
Priyal Rishit Mehta 4.19%unchanged
Haresh K Mehta Huf 0.00%unchanged
Harshit H Mehta Huf 0.00%unchanged
Metasoni Alloys Pvt Ltd —off the list

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Expensive

To justify its price of ₹37, this stock must grow earnings at 22% every year for 7 years. Our analysis caps realistic growth at ~15%. At that growth it is worth ₹26 — downside of 29%.

Growth the price implies
21.7% a year
for 7 years, fading to 4%
It has actually compounded at
14.7% a year
net profit, FY23–FY26 · EPS 15.0%
The gap
0.1 pp
-29% downside if it only repeats history
Price today ₹37.05 Value at the reference growth ₹26.26

Change the assumptions yourself →

Learn to analyse Medico Remedies Limited

Guides on how to read this kind of business and the numbers that matter.